Finance

Lists
ALPMY:OTCMKTS
Astellas Pharma ADR Representing 1 Ord Shs
14,26 USD
-0,66%
(-0,095) 1D
12-окт., 10:40:44 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALPMY...
Open
13,48 USD
High
14,34 USD
Low
13,48 USD
Mkt. cap
4,07 трлн
Avg. vol.
102,64 миң
Volume
19,18 миң
52-wk high
17,35 USD
52-wk low
10,03 USD
Beta
0,13
Shares outstanding
1,81 млд
No. of employees
14 миң
Open
13,48 USD
High
14,34 USD
Low
13,48 USD
Mkt. cap
4,07 трлн
Avg. vol.
102,64 миң
Volume
19,18 миң
52-wk high
17,35 USD
52-wk low
10,03 USD
Beta
0,13
Shares outstanding
1,81 млд
No. of employees
14 миң
News stories
From web sources and news partners
bloomingbit
bloomingbit
·
24 мүнөт мурун
XRP Treasury Firm Evernode Gains 5% in Nasdaq Debut
HME News
HME News
·
21 мүнөт мурун
Accendra Health on notice from NYSE
Profile
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas is a member of the Mitsubishi UFJ Financial Group keiretsu. Wikipedia
About Astellas Pharma ADR Representing 1 Ord Shs
CEONaoki Okamura
Employees14,1 миң
Founded2005-ж., 1-апр.
HeadquartersChuo City, Tokyo, Япония
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
524,32 млд
554,57 млд
537,92 млд
640,91 млд
Cost of goods sold
105,53 млд
104,03 млд
93,67 млд
122,70 млд
Cost of revenue
105,53 млд
104,03 млд
93,67 млд
122,70 млд
Research and development expenses
71,59 млд
85,77 млд
95,94 млд
81,73 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
206,84 млд
228,24 млд
234,70 млд
215,07 млд
Operating expense
325,88 млд
358,98 млд
336,48 млд
332,86 млд
Total operating expenses
431,41 млд
463,01 млд
430,14 млд
455,56 млд
Operating income
92,91 млд
91,55 млд
107,78 млд
185,35 млд
Other non operating income
-
1,50 млн
-241,00 млн
1,00 млн
EBT including unusual items
104,19 млд
90,99 млд
48,02 млд
186,51 млд
EBT excluding unusual items
92,38 млд
90,82 млд
113,57 млд
186,51 млд
Income tax expense
24,98 млд
19,02 млд
4,41 млд
44,76 млд
Effective tax rate
23,97%
20,90%
9,18%
24,00%
Other operating expenses
14,73 млд
9,72 млд
-29,93 млд
388,00 млн
Net income
79,21 млд
71,95 млд
43,52 млд
141,83 млд
Net profit margin
15,11%
12,97%
8,09%
22,13%
Earnings per share
-
-
-
-
Interest and investment income
2,15 млд
2,10 млд
1,29 млд
5,13 млд
Interest expense
-2,69 млд
-2,74 млд
-
-3,12 млд
Net interest expenses
-541,00 млн
-637,00 млн
1,29 млд
2,01 млд
Depreciation and amortization charges
-32,77 млд
-
35,76 млд
-
EBITDA
140,20 млд
141,30 млд
158,14 млд
235,24 млд
Gain or loss from assets sale
16,40 млд
-
31,51 млд
-
AI content may include mistakes. Learn more
Google колдонмолору